TABLE 1.

Clinical studies of the cognitive effects of EPO in psychiatric diseases.

Psychiatric disease	Dosing regimen	Subjects	Tests	Results	References
Schizophrenia	40,000 IU/wk 3 months	39	RBANS, WCST-64	Improved RBANS and WCST-64 No change in psychopathology, social functioning	Ehrenreich et al., Mol Psych:1–15, 2006
Schizophrenia	40,000 IU/wk 3 months	32	RBANS	Halted gray matter loss in the right ventral frontal cortex, ventral striatum and left entorhinal cortex. Improved memory and attention No change in psychopathology	Wustenberg et al., Mol Psych:1–11, 2010
Normal volunteers	40,000 IU - single dose	23	Picture encoding recognition memory	Increased hippocampal activation	Miskowiak et al. (2007b)
Normal volunteers	40,000 IU - single dose	24	Facial recognition self reported mood	Improved facial recognition and mood	Miskowiak et al. (2007a)
Bipolar Disorder	40,000 IU/wk 8 weeks	43	RAVLT, RBANS, RVP WAIS III	No change in verbal fluency Improved attention, processing speed and facial recognition	Miskowiak et al. (2014b)
Major Depression	40,000 IU/wk 8 weeks	31	HDRS-17, GAF, RAVLT BDI-21, WHOQOL-BREF	No change in HDRS-17. Improvement in and verbal memory	Miskowiak et al., Neuropsychopharm 1,399–1,408, 2010
Unipolar Depression Bipolar Disorder	40,000 IU/wk 8 weeks	69	RAVLT	Mood-independent improvement in verbal	Miskowiak et al. (2015)

Clinical studies of erythropoietin in cognition. Shown in the table are details of study populations, dosing regimen employed, number of subjects, tests, results and references. RBANS–Repeatable Battery for the Assessment of Neuropsychological Status, WCST–Wisconsin Card Sorting Test, RAVLT–Rey Auditory Verbal Learning Test, RVP–Rapid Visual Information Processing, WAIS III–Wechsler Adult Intelligence Scale 3^rd edition, HDRS–Hamilton Depression Rating Scale, GAF–Global Assessment of Functioning, BDI–Beck Depression Inventory and WHOQOL-BREF - World Health Organization Quality of Life–Abbreviated.